Your browser doesn't support javascript.
loading
Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial.
Franek, Edward; Gerstein, Hertzel C; Riddle, Matthew C; Nicolay, Claudia; Hickey, Ana; Botros, Fady T; Loo, Li Shen.
Afiliação
  • Franek E; Mossakowski Medical Research Centre, Polish Academy of Sciences and Central Clinical Hospital MSWiA, Warsaw, Poland.
  • Gerstein HC; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
  • Riddle MC; Department of Medicine, Oregon Health & Science University, Portland, Oregon.
  • Nicolay C; Eli Lilly and Company, Indianapolis, Indiana.
  • Hickey A; Eli Lilly and Company, Indianapolis, Indiana.
  • Botros FT; Eli Lilly and Company, Indianapolis, Indiana.
  • Loo LS; Eli Lilly and Company, Indianapolis, Indiana.
Diabetes Obes Metab ; 24(9): 1753-1761, 2022 09.
Article em En | MEDLINE | ID: mdl-35546279
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Hipoglicemiantes Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Hipoglicemiantes Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article